
|Videos|August 30, 2021
Dr. Zhang on risk stratification and treatment selection in mCSPC
Author(s)Urology Times staff
Advertisement
Jingsong Zhang, MD, PhD, discusses contributing factors to risk stratification and subsequent treatment selection in patients with metastatic castration-sensitive prostate cancer. The factors Zhang highlights include site of metastases, PSA response, and metastases burden.
Zhang is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
2
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
3
Initial prostate cancer presentation, family history linked to survival in mCRPC
4
AI system links surgical gestures with postoperative outcomes
5












